Tumor Ablation Market By Technology (Radiofrequency Ablation, Microwave Ablation, Cryoablation, Irreversible Electroporation Ablation, Other Ablation Technologies), By Treatment (Surgical Ablation, Laparoscopic Ablation, Percutaneous Ablation), By Application (Kidney Cancer, Liver Cancer, Breast Cancer, Lung Cancer, Prostate Cancer): Global Opportunity Analysis and Industry Forecast, 2021-2031
The global tumor ablation market was valued at $1,337.2 million in 2021, and is projected to reach $4,655.6 million by 2031, registering a CAGR of 13.6% from 2022 to 2031.
Tumor ablation techniques also referred as a minimally invasive technology, are used to treat tumors of kidneys, bones, liver, and lungs. It uses heat to target a specific tumor cell. It is a needle-like device with a heat-generating component that leads to cellular necrosis of targeted tumor cells. It is performed in-vivo, without taking tumors out of the body. The method eliminates benign tumors by inserting a probe and heating it to 100-degree celsius under precise computer tomography. There are different methods such as microwave, radiofrequency, cryo, and other methods of ablation that can be used for disease diagnosis and treatment. Repeated use of ablation methods helps reduce patient's pain and risk while increasing accuracy and treating a broader region.
The growth of global tumor ablation market is majorly driven by increase in prevalence of cancer, coupled with rise in lifestyle associated diseases. Furthermore, increase in demand for tumor ablation-based treatments is becoming increasingly popular, which propels the market growth. Moreover, adoption and emergence of technologically advanced tumor ablation techniques including the advent of thermal and laser ablation, irreversible electroporation, and high-intensity focused ultrasound (HIFU) are the factors that influence the market growth. Increase in safety regarding use of ablation techniques, increase in geriatric population, and increase in public-private initiatives & funding to support ongoing research activities related to tumor ablation drive the market growth.
According to the National Cancer Institute, U.S., around 1,806,590 new cases of cancer were diagnosed in 2020. The most prevalent cancers in the U.S. are endometrial cancer, leukemia cancer, pancreatic cancer, thyroid cancer, liver cancer, colon & rectum cancer, melanoma of the skin, bladder cancer, kidney & renal pelvis cancer, and breast cancer. In addition, according to the American Cancer Society in 2022, there were 236,740 new instances of lung cancer, making it the third most prevalent type of cancer. Out of these total number of new cases, 117,910 cases involved men and 118,830 cases involved women.
The global tumor ablation market is segmented on the basis of technology, treatment, application, and region. By technology, the market is classified into radiofrequency ablation, microwave ablation, cryo-ablation, irreversible electroporation ablation, and others. By treatment, it is classified into surgical ablation, laparoscopic ablation, and percutaneous ablation. By application, it is classified into kidney cancer, liver cancer, breast cancer, lung cancer, and prostate cancer. By region, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.
Some of the major companies that operate in the global tumor ablation market are Abbott Laboratories, AngioDynamics Inc., Bioventus, Boston Scientific Corporation, ConMed Corporation, Elekta Inc., Galil Medical Inc., HealthTronics Inc., Johnson & Johnson and Medtronic Plc.
KEY BENEFITS FOR STAKEHOLDERS
The study provides an in-depth analysis of the global tumor ablation market along with the current trends and future estimations to explain the imminent investment pockets.
A comprehensive analysis of the factors that drive and restrict the market growth is provided in the report.
A comprehensive quantitative analysis of the industry from 2022 to 2031 is provided to enable the stakeholders to capitalize on the prevailing market opportunities.
Extensive analysis of the key segments of the industry helps to understand the application and products of tumor ablation used across the globe.
Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Key Market Segments
By Treatment
Surgical Ablation
Laparoscopic Ablation
Percutaneous Ablation
By Application
Kidney Cancer
Liver Cancer
Breast Cancer
Lung Cancer
Prostate Cancer
By Technology
Radiofrequency Ablation
Microwave Ablation
Cryoablation
Irreversible Electroporation Ablation
Other Ablation Technologies
By Region
North America
U.S.
Canada
Mexico
Europe
Germany
France
United Kingdom
Italy
Spain
Rest of Europe
Asia-Pacific
Japan
China
Australia
India
South Korea
Rest of Asia-Pacific
LAMEA
Brazil
Saudi Arabia
South Africa
Rest of LAMEA
Key Market Players
Medtronic, Inc.
Boston Scientific Corporation
Smith+Nephew
Integra Life sciences
Angidynamics
Johnson and johnson
ethicon, inc.
Galil Medical Inc.
Misonix Inc.
HealthTronics
Please Note: It will take 7-10 business days to complete the report upon order confirmation.
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: TUMOR ABLATION MARKET, BY TECHNOLOGY
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Radiofrequency Ablation
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Microwave Ablation
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- 4.4 Cryoablation
- 4.4.1 Key market trends, growth factors and opportunities
- 4.4.2 Market size and forecast, by region
- 4.4.3 Market analysis by country
- 4.5 Irreversible Electroporation Ablation
- 4.5.1 Key market trends, growth factors and opportunities
- 4.5.2 Market size and forecast, by region
- 4.5.3 Market analysis by country
- 4.6 Other Ablation Technologies
- 4.6.1 Key market trends, growth factors and opportunities
- 4.6.2 Market size and forecast, by region
- 4.6.3 Market analysis by country
- CHAPTER 5: TUMOR ABLATION MARKET, BY TREATMENT
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Surgical Ablation
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Laparoscopic Ablation
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Percutaneous Ablation
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- CHAPTER 6: TUMOR ABLATION MARKET, BY APPLICATION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 Kidney Cancer
- 6.2.1 Key market trends, growth factors and opportunities
- 6.2.2 Market size and forecast, by region
- 6.2.3 Market analysis by country
- 6.3 Liver Cancer
- 6.3.1 Key market trends, growth factors and opportunities
- 6.3.2 Market size and forecast, by region
- 6.3.3 Market analysis by country
- 6.4 Breast Cancer
- 6.4.1 Key market trends, growth factors and opportunities
- 6.4.2 Market size and forecast, by region
- 6.4.3 Market analysis by country
- 6.5 Lung Cancer
- 6.5.1 Key market trends, growth factors and opportunities
- 6.5.2 Market size and forecast, by region
- 6.5.3 Market analysis by country
- 6.6 Prostate Cancer
- 6.6.1 Key market trends, growth factors and opportunities
- 6.6.2 Market size and forecast, by region
- 6.6.3 Market analysis by country
- CHAPTER 7: TUMOR ABLATION MARKET, BY REGION
- 7.1 Overview
- 7.1.1 Market size and forecast
- 7.2 North America
- 7.2.1 Key trends and opportunities
- 7.2.2 North America Market size and forecast, by Technology
- 7.2.3 North America Market size and forecast, by Treatment
- 7.2.4 North America Market size and forecast, by Application
- 7.2.5 North America Market size and forecast, by country
- 7.2.5.1 U.S.
- 7.2.5.1.1 Market size and forecast, by Technology
- 7.2.5.1.2 Market size and forecast, by Treatment
- 7.2.5.1.3 Market size and forecast, by Application
- 7.2.5.2 Canada
- 7.2.5.2.1 Market size and forecast, by Technology
- 7.2.5.2.2 Market size and forecast, by Treatment
- 7.2.5.2.3 Market size and forecast, by Application
- 7.2.5.3 Mexico
- 7.2.5.3.1 Market size and forecast, by Technology
- 7.2.5.3.2 Market size and forecast, by Treatment
- 7.2.5.3.3 Market size and forecast, by Application
- 7.3 Europe
- 7.3.1 Key trends and opportunities
- 7.3.2 Europe Market size and forecast, by Technology
- 7.3.3 Europe Market size and forecast, by Treatment
- 7.3.4 Europe Market size and forecast, by Application
- 7.3.5 Europe Market size and forecast, by country
- 7.3.5.1 Germany
- 7.3.5.1.1 Market size and forecast, by Technology
- 7.3.5.1.2 Market size and forecast, by Treatment
- 7.3.5.1.3 Market size and forecast, by Application
- 7.3.5.2 France
- 7.3.5.2.1 Market size and forecast, by Technology
- 7.3.5.2.2 Market size and forecast, by Treatment
- 7.3.5.2.3 Market size and forecast, by Application
- 7.3.5.3 United Kingdom
- 7.3.5.3.1 Market size and forecast, by Technology
- 7.3.5.3.2 Market size and forecast, by Treatment
- 7.3.5.3.3 Market size and forecast, by Application
- 7.3.5.4 Italy
- 7.3.5.4.1 Market size and forecast, by Technology
- 7.3.5.4.2 Market size and forecast, by Treatment
- 7.3.5.4.3 Market size and forecast, by Application
- 7.3.5.5 Spain
- 7.3.5.5.1 Market size and forecast, by Technology
- 7.3.5.5.2 Market size and forecast, by Treatment
- 7.3.5.5.3 Market size and forecast, by Application
- 7.3.5.6 Rest of Europe
- 7.3.5.6.1 Market size and forecast, by Technology
- 7.3.5.6.2 Market size and forecast, by Treatment
- 7.3.5.6.3 Market size and forecast, by Application
- 7.4 Asia-Pacific
- 7.4.1 Key trends and opportunities
- 7.4.2 Asia-Pacific Market size and forecast, by Technology
- 7.4.3 Asia-Pacific Market size and forecast, by Treatment
- 7.4.4 Asia-Pacific Market size and forecast, by Application
- 7.4.5 Asia-Pacific Market size and forecast, by country
- 7.4.5.1 Japan
- 7.4.5.1.1 Market size and forecast, by Technology
- 7.4.5.1.2 Market size and forecast, by Treatment
- 7.4.5.1.3 Market size and forecast, by Application
- 7.4.5.2 China
- 7.4.5.2.1 Market size and forecast, by Technology
- 7.4.5.2.2 Market size and forecast, by Treatment
- 7.4.5.2.3 Market size and forecast, by Application
- 7.4.5.3 Australia
- 7.4.5.3.1 Market size and forecast, by Technology
- 7.4.5.3.2 Market size and forecast, by Treatment
- 7.4.5.3.3 Market size and forecast, by Application
- 7.4.5.4 India
- 7.4.5.4.1 Market size and forecast, by Technology
- 7.4.5.4.2 Market size and forecast, by Treatment
- 7.4.5.4.3 Market size and forecast, by Application
- 7.4.5.5 South Korea
- 7.4.5.5.1 Market size and forecast, by Technology
- 7.4.5.5.2 Market size and forecast, by Treatment
- 7.4.5.5.3 Market size and forecast, by Application
- 7.4.5.6 Rest of Asia-Pacific
- 7.4.5.6.1 Market size and forecast, by Technology
- 7.4.5.6.2 Market size and forecast, by Treatment
- 7.4.5.6.3 Market size and forecast, by Application
- 7.5 LAMEA
- 7.5.1 Key trends and opportunities
- 7.5.2 LAMEA Market size and forecast, by Technology
- 7.5.3 LAMEA Market size and forecast, by Treatment
- 7.5.4 LAMEA Market size and forecast, by Application
- 7.5.5 LAMEA Market size and forecast, by country
- 7.5.5.1 Brazil
- 7.5.5.1.1 Market size and forecast, by Technology
- 7.5.5.1.2 Market size and forecast, by Treatment
- 7.5.5.1.3 Market size and forecast, by Application
- 7.5.5.2 Saudi Arabia
- 7.5.5.2.1 Market size and forecast, by Technology
- 7.5.5.2.2 Market size and forecast, by Treatment
- 7.5.5.2.3 Market size and forecast, by Application
- 7.5.5.3 South Africa
- 7.5.5.3.1 Market size and forecast, by Technology
- 7.5.5.3.2 Market size and forecast, by Treatment
- 7.5.5.3.3 Market size and forecast, by Application
- 7.5.5.4 Rest of LAMEA
- 7.5.5.4.1 Market size and forecast, by Technology
- 7.5.5.4.2 Market size and forecast, by Treatment
- 7.5.5.4.3 Market size and forecast, by Application
- CHAPTER 8: COMPANY LANDSCAPE
- 8.1. Introduction
- 8.2. Top winning strategies
- 8.3. Product Mapping of Top 10 Player
- 8.4. Competitive Dashboard
- 8.5. Competitive Heatmap
- 8.6. Key developments
- CHAPTER 9: COMPANY PROFILES
- 9.1 Medtronic, Inc.
- 9.1.1 Company overview
- 9.1.2 Company snapshot
- 9.1.3 Operating business segments
- 9.1.4 Product portfolio
- 9.1.5 Business performance
- 9.1.6 Key strategic moves and developments
- 9.2 Boston Scientific Corporation
- 9.2.1 Company overview
- 9.2.2 Company snapshot
- 9.2.3 Operating business segments
- 9.2.4 Product portfolio
- 9.2.5 Business performance
- 9.2.6 Key strategic moves and developments
- 9.3 Smith+Nephew
- 9.3.1 Company overview
- 9.3.2 Company snapshot
- 9.3.3 Operating business segments
- 9.3.4 Product portfolio
- 9.3.5 Business performance
- 9.3.6 Key strategic moves and developments
- 9.4 Integra Life sciences
- 9.4.1 Company overview
- 9.4.2 Company snapshot
- 9.4.3 Operating business segments
- 9.4.4 Product portfolio
- 9.4.5 Business performance
- 9.4.6 Key strategic moves and developments
- 9.5 Angidynamics
- 9.5.1 Company overview
- 9.5.2 Company snapshot
- 9.5.3 Operating business segments
- 9.5.4 Product portfolio
- 9.5.5 Business performance
- 9.5.6 Key strategic moves and developments
- 9.6 Johnson and johnson
- 9.6.1 Company overview
- 9.6.2 Company snapshot
- 9.6.3 Operating business segments
- 9.6.4 Product portfolio
- 9.6.5 Business performance
- 9.6.6 Key strategic moves and developments
- 9.7 ethicon, inc.
- 9.7.1 Company overview
- 9.7.2 Company snapshot
- 9.7.3 Operating business segments
- 9.7.4 Product portfolio
- 9.7.5 Business performance
- 9.7.6 Key strategic moves and developments
- 9.8 Galil Medical Inc.
- 9.8.1 Company overview
- 9.8.2 Company snapshot
- 9.8.3 Operating business segments
- 9.8.4 Product portfolio
- 9.8.5 Business performance
- 9.8.6 Key strategic moves and developments
- 9.9 Misonix Inc.
- 9.9.1 Company overview
- 9.9.2 Company snapshot
- 9.9.3 Operating business segments
- 9.9.4 Product portfolio
- 9.9.5 Business performance
- 9.9.6 Key strategic moves and developments
- 9.10 HealthTronics
- 9.10.1 Company overview
- 9.10.2 Company snapshot
- 9.10.3 Operating business segments
- 9.10.4 Product portfolio
- 9.10.5 Business performance
- 9.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 2. TUMOR ABLATION MARKET SIZE, FOR RADIOFREQUENCY ABLATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 3. TUMOR ABLATION MARKET FOR RADIOFREQUENCY ABLATION BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 4. TUMOR ABLATION MARKET SIZE, FOR MICROWAVE ABLATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 5. TUMOR ABLATION MARKET FOR MICROWAVE ABLATION BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 6. TUMOR ABLATION MARKET SIZE, FOR CRYOABLATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 7. TUMOR ABLATION MARKET FOR CRYOABLATION BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 8. TUMOR ABLATION MARKET SIZE, FOR IRREVERSIBLE ELECTROPORATION ABLATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 9. TUMOR ABLATION MARKET FOR IRREVERSIBLE ELECTROPORATION ABLATION BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 10. TUMOR ABLATION MARKET SIZE, FOR OTHER ABLATION TECHNOLOGIES, BY REGION, 2021-2031 ($MILLION)
- TABLE 11. TUMOR ABLATION MARKET FOR OTHER ABLATION TECHNOLOGIES BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 12. GLOBAL TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 13. TUMOR ABLATION MARKET SIZE, FOR SURGICAL ABLATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 14. TUMOR ABLATION MARKET FOR SURGICAL ABLATION BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 15. TUMOR ABLATION MARKET SIZE, FOR LAPAROSCOPIC ABLATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 16. TUMOR ABLATION MARKET FOR LAPAROSCOPIC ABLATION BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 17. TUMOR ABLATION MARKET SIZE, FOR PERCUTANEOUS ABLATION, BY REGION, 2021-2031 ($MILLION)
- TABLE 18. TUMOR ABLATION MARKET FOR PERCUTANEOUS ABLATION BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 19. GLOBAL TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 20. TUMOR ABLATION MARKET SIZE, FOR KIDNEY CANCER, BY REGION, 2021-2031 ($MILLION)
- TABLE 21. TUMOR ABLATION MARKET FOR KIDNEY CANCER BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 22. TUMOR ABLATION MARKET SIZE, FOR LIVER CANCER, BY REGION, 2021-2031 ($MILLION)
- TABLE 23. TUMOR ABLATION MARKET FOR LIVER CANCER BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 24. TUMOR ABLATION MARKET SIZE, FOR BREAST CANCER, BY REGION, 2021-2031 ($MILLION)
- TABLE 25. TUMOR ABLATION MARKET FOR BREAST CANCER BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 26. TUMOR ABLATION MARKET SIZE, FOR LUNG CANCER, BY REGION, 2021-2031 ($MILLION)
- TABLE 27. TUMOR ABLATION MARKET FOR LUNG CANCER BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 28. TUMOR ABLATION MARKET SIZE, FOR PROSTATE CANCER, BY REGION, 2021-2031 ($MILLION)
- TABLE 29. TUMOR ABLATION MARKET FOR PROSTATE CANCER BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 30. TUMOR ABLATION MARKET, BY REGION, 2021-2031 ($MILLION)
- TABLE 31. NORTH AMERICA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 32. NORTH AMERICA TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 33. NORTH AMERICA TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 34. NORTH AMERICA TUMOR ABLATION MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 35. U.S. TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 36. U.S. TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 37. U.S. TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 38. CANADA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 39. CANADA TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 40. CANADA TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 41. MEXICO TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 42. MEXICO TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 43. MEXICO TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 44. EUROPE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 45. EUROPE TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 46. EUROPE TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 47. EUROPE TUMOR ABLATION MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 48. GERMANY TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 49. GERMANY TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 50. GERMANY TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 51. FRANCE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 52. FRANCE TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 53. FRANCE TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 54. UNITED KINGDOM TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 55. UNITED KINGDOM TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 56. UNITED KINGDOM TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 57. ITALY TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 58. ITALY TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 59. ITALY TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 60. SPAIN TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 61. SPAIN TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 62. SPAIN TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 63. REST OF EUROPE TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 64. REST OF EUROPE TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 65. REST OF EUROPE TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 66. ASIA-PACIFIC TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 67. ASIA-PACIFIC TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 68. ASIA-PACIFIC TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 69. ASIA-PACIFIC TUMOR ABLATION MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 70. JAPAN TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 71. JAPAN TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 72. JAPAN TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 73. CHINA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 74. CHINA TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 75. CHINA TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 76. AUSTRALIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 77. AUSTRALIA TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 78. AUSTRALIA TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 79. INDIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 80. INDIA TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 81. INDIA TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 82. SOUTH KOREA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 83. SOUTH KOREA TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 84. SOUTH KOREA TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 85. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 86. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 87. REST OF ASIA-PACIFIC TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 88. LAMEA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 89. LAMEA TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 90. LAMEA TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 91. LAMEA TUMOR ABLATION MARKET, BY COUNTRY, 2021-2031 ($MILLION)
- TABLE 92. BRAZIL TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 93. BRAZIL TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 94. BRAZIL TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 95. SAUDI ARABIA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 96. SAUDI ARABIA TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 97. SAUDI ARABIA TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 98. SOUTH AFRICA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 99. SOUTH AFRICA TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 100. SOUTH AFRICA TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 101. REST OF LAMEA TUMOR ABLATION MARKET, BY TECHNOLOGY, 2021-2031 ($MILLION)
- TABLE 102. REST OF LAMEA TUMOR ABLATION MARKET, BY TREATMENT, 2021-2031 ($MILLION)
- TABLE 103. REST OF LAMEA TUMOR ABLATION MARKET, BY APPLICATION, 2021-2031 ($MILLION)
- TABLE 104.MEDTRONIC, INC.: COMPANY SNAPSHOT
- TABLE 105.MEDTRONIC, INC.: OPERATING SEGMENTS
- TABLE 106.MEDTRONIC, INC.: PRODUCT PORTFOLIO
- TABLE 107.MEDTRONIC, INC.: NET SALES,
- TABLE 108.MEDTRONIC, INC.: KEY STRATERGIES
- TABLE 109.BOSTON SCIENTIFIC CORPORATION: COMPANY SNAPSHOT
- TABLE 110.BOSTON SCIENTIFIC CORPORATION: OPERATING SEGMENTS
- TABLE 111.BOSTON SCIENTIFIC CORPORATION: PRODUCT PORTFOLIO
- TABLE 112.BOSTON SCIENTIFIC CORPORATION: NET SALES,
- TABLE 113.BOSTON SCIENTIFIC CORPORATION: KEY STRATERGIES
- TABLE 114.SMITH+NEPHEW: COMPANY SNAPSHOT
- TABLE 115.SMITH+NEPHEW: OPERATING SEGMENTS
- TABLE 116.SMITH+NEPHEW: PRODUCT PORTFOLIO
- TABLE 117.SMITH+NEPHEW: NET SALES,
- TABLE 118.SMITH+NEPHEW: KEY STRATERGIES
- TABLE 119.INTEGRA LIFE SCIENCES: COMPANY SNAPSHOT
- TABLE 120.INTEGRA LIFE SCIENCES: OPERATING SEGMENTS
- TABLE 121.INTEGRA LIFE SCIENCES: PRODUCT PORTFOLIO
- TABLE 122.INTEGRA LIFE SCIENCES: NET SALES,
- TABLE 123.INTEGRA LIFE SCIENCES: KEY STRATERGIES
- TABLE 124.ANGIDYNAMICS: COMPANY SNAPSHOT
- TABLE 125.ANGIDYNAMICS: OPERATING SEGMENTS
- TABLE 126.ANGIDYNAMICS: PRODUCT PORTFOLIO
- TABLE 127.ANGIDYNAMICS: NET SALES,
- TABLE 128.ANGIDYNAMICS: KEY STRATERGIES
- TABLE 129.JOHNSON AND JOHNSON: COMPANY SNAPSHOT
- TABLE 130.JOHNSON AND JOHNSON: OPERATING SEGMENTS
- TABLE 131.JOHNSON AND JOHNSON: PRODUCT PORTFOLIO
- TABLE 132.JOHNSON AND JOHNSON: NET SALES,
- TABLE 133.JOHNSON AND JOHNSON: KEY STRATERGIES
- TABLE 134.ETHICON, INC.: COMPANY SNAPSHOT
- TABLE 135.ETHICON, INC.: OPERATING SEGMENTS
- TABLE 136.ETHICON, INC.: PRODUCT PORTFOLIO
- TABLE 137.ETHICON, INC.: NET SALES,
- TABLE 138.ETHICON, INC.: KEY STRATERGIES
- TABLE 139.GALIL MEDICAL INC.: COMPANY SNAPSHOT
- TABLE 140.GALIL MEDICAL INC.: OPERATING SEGMENTS
- TABLE 141.GALIL MEDICAL INC.: PRODUCT PORTFOLIO
- TABLE 142.GALIL MEDICAL INC.: NET SALES,
- TABLE 143.GALIL MEDICAL INC.: KEY STRATERGIES
- TABLE 144.MISONIX INC.: COMPANY SNAPSHOT
- TABLE 145.MISONIX INC.: OPERATING SEGMENTS
- TABLE 146.MISONIX INC.: PRODUCT PORTFOLIO
- TABLE 147.MISONIX INC.: NET SALES,
- TABLE 148.MISONIX INC.: KEY STRATERGIES
- TABLE 149.HEALTHTRONICS: COMPANY SNAPSHOT
- TABLE 150.HEALTHTRONICS: OPERATING SEGMENTS
- TABLE 151.HEALTHTRONICS: PRODUCT PORTFOLIO
- TABLE 152.HEALTHTRONICS: NET SALES,
- TABLE 153.HEALTHTRONICS: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.TUMOR ABLATION MARKET SEGMENTATION
- FIGURE 2.TUMOR ABLATION MARKET,2021-2031
- FIGURE 3.TUMOR ABLATION MARKET,2021-2031
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.TUMOR ABLATION MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.TUMOR ABLATION MARKET,BY TECHNOLOGY,2021(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF RADIOFREQUENCY ABLATION TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF MICROWAVE ABLATION TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 15.COMPARATIVE SHARE ANALYSIS OF CRYOABLATION TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF IRREVERSIBLE ELECTROPORATION ABLATION TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF OTHER ABLATION TECHNOLOGIES TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 18.TUMOR ABLATION MARKET,BY TREATMENT,2021(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF SURGICAL ABLATION TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF LAPAROSCOPIC ABLATION TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 21.COMPARATIVE SHARE ANALYSIS OF PERCUTANEOUS ABLATION TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 22.TUMOR ABLATION MARKET,BY APPLICATION,2021(%)
- FIGURE 23.COMPARATIVE SHARE ANALYSIS OF KIDNEY CANCER TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 24.COMPARATIVE SHARE ANALYSIS OF LIVER CANCER TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 25.COMPARATIVE SHARE ANALYSIS OF BREAST CANCER TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 26.COMPARATIVE SHARE ANALYSIS OF LUNG CANCER TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 27.COMPARATIVE SHARE ANALYSIS OF PROSTATE CANCER TUMOR ABLATION MARKET,2021-2031(%)
- FIGURE 28.TUMOR ABLATION MARKET BY REGION,2021
- FIGURE 29.U.S. TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 30.CANADA TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 31.MEXICO TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 32.GERMANY TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 33.FRANCE TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 34.UNITED KINGDOM TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 35.ITALY TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 36.SPAIN TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 37.REST OF EUROPE TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 38.JAPAN TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 39.CHINA TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 40.AUSTRALIA TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 41.INDIA TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 42.SOUTH KOREA TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 43.REST OF ASIA-PACIFIC TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 44.BRAZIL TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 45.SAUDI ARABIA TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 46.SOUTH AFRICA TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 47.REST OF LAMEA TUMOR ABLATION MARKET,2021-2031($MILLION)
- FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 52.COMPETITIVE DASHBOARD
- FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 54.MEDTRONIC, INC..: NET SALES ,($MILLION)
- FIGURE 55.BOSTON SCIENTIFIC CORPORATION.: NET SALES ,($MILLION)
- FIGURE 56.SMITH+NEPHEW.: NET SALES ,($MILLION)
- FIGURE 57.INTEGRA LIFE SCIENCES.: NET SALES ,($MILLION)
- FIGURE 58.ANGIDYNAMICS.: NET SALES ,($MILLION)
- FIGURE 59.JOHNSON AND JOHNSON.: NET SALES ,($MILLION)
- FIGURE 60.ETHICON, INC..: NET SALES ,($MILLION)
- FIGURE 61.GALIL MEDICAL INC..: NET SALES ,($MILLION)
- FIGURE 62.MISONIX INC..: NET SALES ,($MILLION)
- FIGURE 63.HEALTHTRONICS.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook